Izabel Almeida Alves

Izabel Almeida Alves

Auto-generated profile, based on publicly available information

Izabel Almeida Alves

Universidade Federal da Bahia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
LPLaiz Campos Pereira
Laiz Campos Pereira
MFMarcelo Aguiar de Fátima
Marcelo Aguiar de Fátima
VSValdeene Vieira Santos
Valdeene Vieira Santos
CBCarolina Magalhaes Brandao
Carolina Magalhaes Brandao
IAIzabel Almeida Alves
Izabel Almeida Alves
FAFrancine Johansson Azeredo
Francine Johansson Azeredo
Pharmacokinetics and pharmacodynamics are areas in pharmacology related to different themes in the pharmaceutical sciences, including therapeutic drug monitoring and different stages of drug development. Although the knowledge of these disciplines is essential, they have historically been treated separately. While pharmacokinetics was limited to describing the time course of plasma concentrations after administering a drug-dose, pharmacodynamics describes the intensity of the response to these concentrations. In the last decades, the concept of pharmacokinetic/pharmacodynamic modeling (PK/PD) emerged, which seeks to establish mathematical models to describe the complete time course of the dose-response relationship. The integration of these two fields has had applications in optimizing dose regimens in treating antibacterial and antifungals. The anti-infective PK/PD models predict the relationship between different dosing regimens and their pharmacological activity. The reviewed studies show that PK/PD modeling is an essential and efficient tool for a better understanding of the pharmacological activity of antibacterial and antifungal agents.

14 March 2025 in Toxins
Verified
Journal Article
Open access
PDF file
DRDiana Carolina Zona Rubio
Diana Carolina Zona Rubio
Marcela AragonMarcela Aragon
Marcela Aragon
IAIzabel Almeida Alves
Izabel Almeida Alves
Active compounds from natural sources, particularly snake venoms, are crucial for pharmaceutical development despite challenges in drug discovery. Snake venoms, historically used for medicinal purposes, contain bioactive peptides and enzymes that show therapeutic potential for conditions such as arthritis, asthma, cancer, chronic pain, infections and cardiovascular diseases. The objective of this study was to examine pharmacological and biomedical innovations by identifying the key research trends, the most studied snake species, and their therapeutic applications. A systematic review of patents related to snake venoms was conducted using the European Patent Office database, Espacenet, covering 2014 to mid-2024. The search employed the keyword “venom,” applying IPC classification A61K38/00, resulting in 31 patents after screening. A PubMed survey on “snake venom derivatives innovations” was conducted to compare the scientific literature volume with the identified patents. This review highlights the therapeutic potential of snake venom-derived products for coagulation disorders, cancer, inflammation, and pain management. Despite challenges in pharmacokinetics and venom variability, advancements in biotechnology offer promise for personalized therapies. The future of snake venom-based treatments appears promising for addressing complex medical conditions.

1 August 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
ABAna Paula Rosinski Bueno
Ana Paula Rosinski Bueno
FSFlavia Medeiros Savi
Flavia Medeiros Savi
IAIzabel Almeida Alves
Izabel Almeida Alves
VBVanessa Adelina Casali Bandeira
Vanessa Adelina Casali Bandeira
Background: Insomnia is a sleep disorder characterized by difficulty of falling asleep or maintaining sleep, which affects different age groups. Currently, melatonin is used as a therapeutic treatment in cases of insomnia in children, adults, and elderly people. Objective: To evaluate the effectiveness of melatonin in sleep disorders, its dosage, potential adverse effects, as well as labeling laws and regulations in Brazil. Methods: This integrative review was carried out using the Cochrane Library, Medline (Pubmed), and Science Direct databases. Twenty-five articles and three documents available on the Brazilian Society of Endocrinology and Metabology (SBEM) and National Health Surveillance Agency (ANVISA) websites published between 2015 and 2020 were selected to be evaluated in full. Results: It was found that in most of the selected articles the use of melatonin reduces sleep latency. The effective melatonin doses varied according to each age group, from 0.5 to 3 mg in children, 3 to 5 mg in adolescents, 1 to 5 mg in adults, and 1 to 6 mg in elderly people. Side effects are mild when taking usual doses. In Brazil, no registered drug and current regulation on the use and marketing of melatonin has been identified. Conclusion: The use of melatonin is an alternative therapy that can be used for sleeping disorders. According to the evidences found, it did not demonstrate toxicity or severe side effects, nor dependence even when administered at high doses, suggesting that it is a safe medication to treat patients of different ages suffering from sleeping disorders.

27 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
IRIngrid Andrea Rodriguez
Ingrid Andrea Rodriguez
MSMairim Russo Serafini
Mairim Russo Serafini
IAIzabel Almeida Alves
Izabel Almeida Alves
KLKaren Luise Lang
Karen Luise Lang
FSFátima Regina Mena Barreto Silva
Fátima Regina Mena Barreto Silva
Marcela AragonMarcela Aragon
Marcela Aragon
Diabetes mellitus (DM) is a metabolic syndrome that can be considered a growing health problem in the world. High blood glucose levels are one of the most notable clinical signs. Currently, new therapeutic alternatives have been tackled from clinicians’ and scientists’ points of view. Natural products are considered a promising source, due to the huge diversity of metabolites with pharmaceutical applications. Therefore, this review aimed to uncover the latest advances in this field as a potential alternative to the current therapeutic strategies for the treatment of DM. This purpose is achieved after a patent review, using the Espacenet database of the European Patent Office (EPO) (2016–2022). Final screening allowed us to investigate 19 patents, their components, and several technology strategies in DM. Plants, seaweeds, fungi, and minerals were used as raw materials in the patents. Additionally, metabolites such as tannins, organic acids, polyphenols, terpenes, and flavonoids were found to be related to the potential activity in DM. Moreover, the cellular transportation of active ingredients and solid forms with special drug delivery profiles is also considered a pharmaceutical technology strategy that can improve their safety and efficacy. From this perspective, natural products can be a promissory source to obtain new drugs for DM therapy.

8 May 2025 in Photochemical & Photobiological Sciences
Verified
Journal Article
Closed access
PDF file
Vanessa Urrea-VictoriaVanessa Urrea-Victoria
Vanessa Urrea-Victoria
AHAura Hernández
Aura Hernández
LCLeonardo Castellanos
Leonardo Castellanos
IAIzabel Almeida Alves
Izabel Almeida Alves
Marcela AragonMarcela Aragon
Marcela Aragon

2 February 2021 in Critical Reviews in Biotechnology
Verified
Journal Article
Closed access
MSMairim Russo Serafini
Mairim Russo Serafini
VSValdeene Vieira Santos
Valdeene Vieira Santos
BTBruna Gaelzer Silva Torres
Bruna Gaelzer Silva Torres
FAFrancine Johansson Azeredo
Francine Johansson Azeredo
FSFlavia Medeiros Savi
Flavia Medeiros Savi
IAIzabel Almeida Alves
Izabel Almeida Alves
Fungal biofilms, such as Candida albicans biofilms, are capable of surviving in hostile environments owing to their remarkable ability to adhere to surfaces and their tolerance to chemical interventions. Currently, therapeutic treatment options are few, making these biofilm-based infections problematic particularly due to their great tolerance to conventional antimicrobial drugs, thus causing serious health and economic problems. Therefore, the development of new drugs and antibiofilm specific therapies for the prevention and treatment of antifungal to eradicate biofilms are needed. This study was aimed at carrying out a patent review analysis to identify the innovation trends, and to explore the latest antifungal drugs and the specific therapeutic strategies available for the treatment of fungal biofilms. The present patent review was carried out using the Espacenet database, using the key words “biofilm and antifungal,” from 2002 to December 2019. Through this review, it was possible to identify that most of the patent contents refer to new synthetic drugs derived from natural products and associations thereof with existing antifungal drugs. Methods and biomaterials for the treatment and prevention of fungal biofilms, mainly for C. albicans biofilms, which is the most isolated and studied fungal species, were also disclosed. The lack of scientific and technical information on the biofilm eradication subject is remarkable and further confirmed by the small number of patents identified in this survey.